Form 4: Precision BioSciences CEO Receives Restricted Stock Units

Michael Amoroso, President and CEO of Precision BioSciences, has been granted 573,888 restricted stock units, vesting over three years.

Summary

• Michael Amoroso, President and CEO of Precision BioSciences, Inc., was granted 573,888 restricted stock units (RSUs) on June 1, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The award vests in three substantially equal annual installments, commencing on February 18, 2027.
• Vesting is contingent upon Mr. Amoroso's continued service to the Issuer through each applicable vesting date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard executive compensation practices rather than significant financial performance or strategic shifts.

Positives

• Grant of a significant number of restricted stock units to the CEO, indicating a long-term incentive and alignment with company performance.
• The vesting schedule over three years encourages retention and sustained commitment from leadership.

Negatives

• The RSUs are contingent and subject to continued employment, meaning the full award is not guaranteed if service is terminated before vesting dates.

Risks

• Potential for forfeiture of unvested RSUs if the reporting person's service to the Issuer terminates before the vesting dates.
• The value of the RSUs is tied to the future performance and stock price of Precision BioSciences, which carries inherent market risks.

Future Outlook

The vesting of these restricted stock units is tied to continued service, suggesting management's expectation of ongoing operations and the reporting person's continued role within the company.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units to executive leadership is a common practice in the biotechnology sector to incentivize long-term growth and align executive interests with shareholder value, especially for companies focused on R&D and product development.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term company performance, potentially benefiting shareholders if the stock price increases.
• Employees: May signal stability in leadership, though the direct impact on other employees is minimal.
• Management: Provides a significant incentive for the CEO to remain with the company and drive performance.

Next Steps

• Continued service by Michael Amoroso to meet vesting requirements for the restricted stock units.
• Annual vesting of restricted stock units beginning February 18, 2027, subject to continued service.

Key Dates

Keywords

Restricted Stock Units, CEO Compensation, Equity Award, Precision BioSciences, DTIL, Executive Compensation, Stock Options, Vesting Schedule